• Pharmaxis Ltd., of Sydney, Australia, said the National Institute for Health and Clinical Excellence in the UK issued a positive recommendation in its final appraisal determination for Bronchitol (mannitol dry powder for inhalation), approved to treat adult cystic fibrosis patients as an add-on therapy to best standard of care.